Soleno Therapeutics, Inc.
NASDAQ:SLNO
53.55 (USD) • At close September 18, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Soleno Therapeutics, Inc. |
Symbool | SLNO |
Munteenheid | USD |
Prijs | 53.55 |
Beurswaarde | 2,081,574,180 |
Dividendpercentage | 0% |
52-weken bereik | 3.96 - 54.5 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Anish Bhatnagar M.D. |
Website | https://soleno.life |
An error occurred while fetching data.
Over Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)